Explore more publications!
Everything Worth Reading
Got News to Share?

Press Releases

Biomarkers Market Size to Surpass USD 366.64 Billion by 2035 | Nova One Advisor
10 hours ago

Biomarkers Market Size to Surpass USD 366.64 Billion by 2035 | Nova One Advisor

Indeterminate GlobeNewswire, Inc.
EC Publishing Announces Global Book Fair Series in Taiwan, London, and Los Angeles
Jan. 15, 2026

EC Publishing Announces Global Book Fair Series in Taiwan, London, and Los Angeles

Neutral EIN Presswire
Award-Winning Author and Philosophy Professor Claudia Mills Brings Ancient Stoic Wisdom to Young Readers in New Novel
Jan. 15, 2026

Award-Winning Author and Philosophy Professor Claudia Mills Brings Ancient Stoic Wisdom to Young Readers in New Novel

Neutral EIN Presswire
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
12 hours ago

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

Indeterminate GlobeNewswire, Inc.
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
Jan. 14, 2026

Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology

Indeterminate GlobeNewswire, Inc.
Mars Veterinary Health Publishes 2025 Science Impact Report Highlighting Global Advances in Pet Health
Jan. 14, 2026

Mars Veterinary Health Publishes 2025 Science Impact Report Highlighting Global Advances in Pet Health

Indeterminate GlobeNewswire, Inc.
Ohio eIPP Proposal Uses New Aviation Technology to Solve National Healthcare Challenge
11 hours ago

Ohio eIPP Proposal Uses New Aviation Technology to Solve National Healthcare Challenge

Indeterminate GlobeNewswire, Inc.
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
Jan. 14, 2026

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Indeterminate GlobeNewswire, Inc.
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Jan. 14, 2026

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Indeterminate GlobeNewswire, Inc.
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
12 hours ago

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

Indeterminate GlobeNewswire, Inc.
Author Trisha McAfee Releases New Psychological Thriller Tappan Lake: Beneath the Surface
Jan. 6, 2026

Author Trisha McAfee Releases New Psychological Thriller Tappan Lake: Beneath the Surface

Neutral EIN Presswire
Author Viktor Ujkic Releases a Debut Novel ‘Justice Died at Dawn’ Set in a Broken Justice System
Jan. 6, 2026

Author Viktor Ujkic Releases a Debut Novel ‘Justice Died at Dawn’ Set in a Broken Justice System

Neutral EIN Presswire
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Jan. 28, 2026

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Indeterminate GlobeNewswire, Inc.
NetraMark Closes First Tranche of Private Placement
12 hours ago

NetraMark Closes First Tranche of Private Placement

Indeterminate GlobeNewswire, Inc.
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
Jan. 12, 2026

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Indeterminate GlobeNewswire, Inc.
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
Jan. 12, 2026

New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal

Indeterminate GlobeNewswire, Inc.
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Jan. 12, 2026

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

Indeterminate GlobeNewswire, Inc.
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
12 hours ago

Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

Indeterminate GlobeNewswire, Inc.
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
13 hours ago

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Indeterminate GlobeNewswire, Inc.
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
12 hours ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions